The question of whether caloric restriction (CR) is hermetic is addressed i
n terms of two common definitions of the term. In terms of the older defini
tion, i.e., a growth-stimulatory effect when lower doses of a compound whic
h resulted in growth inhibition at higher doses, CR is better characterized
as a co-hormetic (i.e., a paradigm which at relatively "low doses," in com
bination with some stimulus, will evince increased growth (proliferation) a
nd at higher "doses" will inhibit this increased proliferation) rather than
a hermetic agent. Mechanisms such as cellular selection of cellular subpop
ulations, increases in receptor efficiency, and preservation of cellular pr
oliferative potential can interact with agents and produce increased growth
as long as the CR is not too severe.
In terms of a broader definition, i.e., nonmonotonic dose-response behavior
of a compound for any adverse response, CR appears to be hermetic, both as
a result of body weight (BW) loss and other potential mechanisms. The impa
ct of changes in BW, or frank CR, can be considered a component of every te
st for hormesis, and is thus capable for interaction with any other agent.
The changes that BW loss (or CR) induce are so profound that any aspect of
an agent's action - metabolism, pharmacokinetics, pharmacodynamics - can mo
dulate the response of an organism to an agent. Similarly, other effects of
a chemical that induce BW loss, e.g., physical activity or temperature dys
regulation, can also induce dose-response curves that appear hermetic. The
interaction of the hermetic agents of BW loss and CR can influence agent te
sts.
Controlling these factors may make it possible to dissect the key component
s of a hermetic response. In addition, the effects of CR or BW loss appear
to extrapolate well across species [Colman R, Kemnitz JW. Aging experiments
using nonhuman primates. In: Yu BP (Ed), Methods in Aging Research. CRC Pr
ess, Boca Raton, FL, 1999, pp. 249-267]. Thus there is some reason to belie
ve that these hermetic factors may be important for humans, and may already
be a factor for tests of adverse agents already conducted in humans.